Electra Therapeutics (NASDAQ:ETRA) Director Buys $387,915.60 in Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon bought 49,416 shares of the stock in a transaction on Friday, November 6th. The shares were acquired at an average cost of $7.85 per share, for a total transaction of $387,915.60. Following the acquisition, the director directly owned 5,230,578 shares in the company, valued at approximately $41,060,037.30. This trade represents a 0.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Electra Therapeutics Stock Performance

NASDAQ:ETRA opened at $9.11 on Friday. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Electra Therapeutics (NASDAQ:ETRA) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($3.47) earnings per share for the quarter, missing the consensus estimate of ($1.76) by ($1.71). Research analysts expect that Electra Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on ETRA shares. Cantor Fitzgerald began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set an “overweight” rating on the stock. Evercore assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 target price for the company. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. HC Wainwright initiated coverage on shares of Electra Therapeutics in a report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.